Spherics' proprietary anhydride based hydrophobic thermoplastic polymers,Spheromers (TM), have superior conventional hydrophilic bioadhesive polymers.These polymers improve drug performance by ...

With SRx-503, Spherics has developed an improved version of a first andsecond line treatment for Parkinson's disease. Current global sales exceed$700 million (approx. $600 million US only ...

Spherics also helps SMBs apply carbon emission factors to procurement categories (such as delivery, accommodation, electricity and travel) to estimate the associated carbon footprint of a transaction.

Business software specialist Sage has this week announced the acquisition of Spherics, a firm specialising in carbon accounting, in a move designed to help small and medium-sized businesses (SMBs ...

Spherics, a U.K.-based carbon accounting platform for SMEs to understand and reduce their environmental impact, has been acquired by accounting giant Sage. Terms of the deal were not disclosed but ...

Spherics is using bioadhesion encapsulation to enable drug-uptake in the gastrointestinal tract. The technology allows large-molecule drugs administered intravenously to be given orally.

Spherics Inc., Lincoln, R.I., secured $10 million in Series B funding. Zero Stage Capital, CB Health Ventures, PODHolding Inc., and Eastman Ventures all took part in the round. The money will be ...

Sage announced it has acquired carbon accounting solution Spherics, as part of the company's drive towards sustainability. The solution is marketed primarily to small and medium businesses. The ...

Spherics also helps SMBs apply carbon emission factors to procurement categories (such as delivery, accommodation, electricity and travel) to estimate the associated carbon footprint of a transaction.

Spherics Inc., a Mansfield, Mass.-based developer of oral drugs for neurological disorders, will put its intellectual property up for auction on October 10, according to an accoun ...